Skip to main content

Write a PREreview

Strong at Home, Going Global: China’s Rise in Immune Checkpoint Therapy Patents, 2010–2023

Posted
Server
Preprints.org
DOI
10.20944/preprints202611.0810.v1

Background. Immune checkpoint inhibitors changed cancer treatment, and the patents behind them shape who can develop the next generation of these drugs. China’s role in checkpoint drug development and licensing has grown quickly, but its share of checkpoint patenting, where Chinese applicants seek protection and what they protect have not been measured systematically.Methods. We analysed 3,320 patent documents on immune checkpoint therapy exported from Lens.org in January 2024 (application years 1997–2023). We measured the share of documents with Chinese and US applicants over time, the patent office where each document was filed, the size of its patent family, and what each country protects, using keyword labels for checkpoint targets and therapeutic strategies checked against 200 hand-coded documents. We tested the main result with five robustness checks. Results. The share of documents with a Chinese applicant rose from 21.6% (95% CI 16.8–27.3) in 2015–16 to 39.1% (36.2–41.9) in 2020–21, while the US share fell from 50.8% to 35.4%; China overtook the United States in 2020. China’s share also nearly doubled outside the Chinese patent office (9.1% to 17.7%; p = 0.004). Yet in 2010–2021, 70.1% of Chinese documents were filed in the Chinese office, Chinese applicants used the international PCT route half as often as US applicants (13.5% vs 26.9%), and Chinese patent families were smaller (median 2 vs 7 documents). Chinese documents more often named PD-1 (55.5% vs 42.9%) and PD-L1 (44.6% vs 30.5%) and more often described bispecific molecules (10.6% vs 4.2%), including 19 of the 21 PD-1/PD-L1 × VEGF bispecific documents. US documents more often described combination therapies (53.8% vs 33.5%) and CTLA-4 (14.6% vs 8.7%). Conclusions. China became the largest source of immune checkpoint patent filings in 2020. Most of its filings protect the home market and focus on the PD-1 axis and bispecific formats, the same formats that later drove large international licensing deals. An open interactive explorer with all data is available at cognosx.ca/dashboards/immune-checkpoint.

You can write a PREreview of Strong at Home, Going Global: China’s Rise in Immune Checkpoint Therapy Patents, 2010–2023. A PREreview is a review of a preprint and can vary from a few sentences to a lengthy report, similar to a journal-organized peer-review report.

Before you start

We will ask you to log in with your ORCID iD. If you don’t have an iD, you can create one.

What is an ORCID iD?

An ORCID iD is a unique identifier that distinguishes you from everyone with the same or similar name.

Start now